Diflunisal Offlabel denied for failing step therapy by Humana?

Humana's specific coverage criteria for diflunisal offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Step Therapy to Off-Label Diflunisal

Step therapy — sometimes called "fail-first" — requires a patient to try one or more designated alternative treatments before the plan will authorize the requested drug. For off-label diflunisal use, Humana's step therapy protocol typically requires that preferred or lower-cost agents be tried and documented as failed or contraindicated before approval. A step-therapy denial means Humana's reviewer did not find sufficient evidence in the PA submission that the required prior steps have been completed.

## Why This Is Appealable

Step-therapy denials are among the most commonly overturned on appeal. They are overturned when the documentation shows: (a) the required prior drugs were tried and failed; (b) the required prior drugs are contraindicated for this patient; or (c) the patient's condition is clinically urgent enough that step therapy would cause serious harm. Many states — and CMS for Medicare Advantage plans — have enacted step-therapy override protections that create a right to an expedited exception when prior steps are documented.

## Federal Appeal Framework

• Internal appeal: File within 180 days. For prospective denials, Humana must respond within 15 days (standard) or 72 hours (urgent/expedited).
• Step-therapy override rights: Humana is subject to applicable state or federal step-therapy exception laws. For Medicare Advantage, CMS regulations provide explicit exception pathways. Review which law applies to your plan.
• External review (ACA §2719): Request independent external review within 4 months of final internal denial. IRO decision is binding.
• ERISA §503 (self-funded plans): Full-and-fair review applies; federal courts can review procedural violations.

## Documentation to Gather

1. Step therapy history log — a complete, dated list of every required prior agent tried, including start date, stop date, doses (as documented in the chart), and the specific reason each was inadequate (adverse effect, insufficient response, contraindication). 2. Prescriber attestation — a letter from the prescriber affirming which steps have been completed and why the patient cannot safely or effectively continue with those agents. 3. Chart notes and lab results — objective documentation supporting the failure or contraindication narrative for each prior step. 4. Clinical urgency documentation — if the patient's condition warrants expedited exception, chart notes quantifying severity and the risk of delay. 5. Humana's step-therapy protocol — obtained from Humana's provider or member portal, so the appeal responds directly to each required step.

## Criteria-Mapping Structure

Pull Humana's current step-therapy criteria for this drug and indication and map each step:

| Required Step (from Humana policy) | Documentation of Completion or Exception Basis | |---|---| | Step 1 agent tried | [Dates, chart note, reason stopped] | | Step 2 agent tried or contraindicated | [Dates / contraindication documentation] | | Clinical urgency or exception basis | [Prescriber letter, severity assessment] |

The live policy is the controlling document — always use the current version when structuring your appeal.